

Improving the clinical trial experience for patients and investigators through a simulated trial in palmoplantar pustulosis (PPP)

¹EUROPSO, European Umbrella Federation for Psoriasis Associations, Polzela, Slovenia; ²Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany; ³Canadian Association of Psoriasis Patients, Ottawa, ON, Canada; ⁴Department of Dermatology, Venereology, University Hospital Frankfurt am Main, Frankfurt am Main, Frankfurt am Main, Germany; ³Canadian Association of Psoriasis Patients, Ottawa, ON, Canada; ⁴Department of Dermatology, Venereology, Vener Seibo International Catholic Hospital, Tokyo, Japan; ⁵National Psoriasis Foundation, Portland, OR, USA; ⁶Boehringer Ingelheim, Germany; ⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; ⁸Nippon Boehringer Ingelheim Co. Ltd, Tokyo, Japan; ⁹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; ⁸Nippon Boehringer Ingelheim Co. Ltd, Tokyo, Japan; ⁹Boehringer Ingelheim International GmbH, Biberach, Germany; ¹⁰Department of Dermatology, Radboud University, Nijmegen, the Netherlands



Involving patients in trial design can help overcome challenges of clinical trial recruitment and retention, which are particularly relevant for rare diseases, and improve patient outcomes. This simulated trial shows that patients value clear, concise, and non-technical literature, efficient trial visits, and the option to continue effective treatment after study completion

PURPOSE


To evaluate the experiences and perceptions of patients with PPP participating in a simulated clinical trial and inform and enhance future, patient-centric trial designs.

INTRODUCTION

- Seeking and implementing patient feedback on clinical trial design can enhance the patients' experience and improve outcomes by reducing drop-out rates and associated costs, and allowing collection of more robust data¹⁻⁴
- Challenges in recruiting and retaining patients are amplified in rare diseases, where there are fewer patients across a wider geographic spread,⁵ making appropriate trial design even more important
- PPP, a rare, debilitating disease, 6-8 is an ideal candidate for conducting a simulated trial to refine the design before initiating recruitment for a full clinical trial

CONCLUSIONS

- Barriers to recruitment that were highlighted by patients with PPP in this simulated clinical trial included pre-trial literature, likelihood of assignment to placebo, visit schedules and logistics, and outcome measures
- Solutions were to develop study materials with simpler language and visual aids; incorporate open-label extensions or cross-over options; reduce the number and increase the efficiency of study visits; and provide greater financial support
- These simple patient- and investigator-focused improvements may inform future PPP trial designs, optimize the patient experience, and support generation of robust data
- Importantly, these insights are potentially applicable to other therapeutic areas and could be used for wide-ranging improvements to trial design



'Questionnaires included disease-specific measures (BASDAI, DLQI, PSS, ppQLI, and PBI-S), general health-related quality of life measures (SF-36, EQ-5D-5L), and three newly developed pain NRS; ¹The participants included 3 members of the patient advisory committee involved in developmen of the simulated trial, 7/9 patients who participated in the virtual trial simulation, and 4 additional patient representatives

RESULTS

Demographic and clinical characteristics of patient participants

- Nine patients participated in the trial simulation, and 14 patients or patient representatives took part in the advisory boards, of whom 10 were living with PPP
- Patients participating in the trial simulation were mostly female (n=8, 88.9%) and had not participated in a clinical trial (n=7, 77.8%); mean (range) age at diagnosis was 42.6 years (25–73); mean (range) duration of disease was 16.4 years (4–35); and most were currently receiving PPP treatment with biologics (n=4, 44.4%) or topicals (n=4, 44.4%)

Patient feedback on the ICF and recruitment materials



kind of get lost, glazed over, when I start reading about all of that coding of your data. You could just say, 'We do this' or, 'We do that' instead of saying it in longhand 🦷







I have been in the clinical trial out I didn't read the consent form. I had no time to read 📭




An animated video what is the clinical trial, what is the placebo, what is the consent form, what is the highlights from the consent form. So instead of a brochure I think it's better a video 🛺

Patients felt the ICF was too long and recommended using less technical language and visual media for recruitment materials; discussion with an HCP was considered beneficial

Patient feedback on the trial visit schedule and logistics



The duration of the visit. Because I thought that was crazy, ridiculous. Three and a half hours for a maintenance visit. Nobody's going to spend half a day at the doctors



...how many appointments are in one year? Maybe 12 or 18? [A participant] would have to take so many days off. Let's just imagine 18 days, you would have to think about what kind of options are there [and] how to compensate somebody for that ,

It's just an infringement on my day-to-day life. So, those visits would determine my life living, that is not what I like "

Asking patients to attend 20 visits lasting approximately 2–3 hours each was considered excessive, especially as waiting times are often long. Patients felt that logistical and financial support were crucial in enabling trial participation

Abbreviations

BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; DLQI, Dermatology Life Quality Index; HCP, healthcare professional; ICF, informed consent form; NRS, numerical rating scale; PBI-S, Patient Benefit Index – Standard; PPP, palmoplantar pustulosis; ppQLI, Palmoplantar Quality of Life Instrument; PRO, patient-reported outcomes; PSS, Psoriasis Symptom Scale; SF-36, Short Form 36.


References 1. Sharma NS. Perspect Clin Res 2015;6:134–138; 2. Treweek S, et al. Cochrane Database Syst Rev 2018;2:MR000013; 3. Awwad O, et al. Int J Clin Pract 2021;75:e13687; 4. Lim SS, et al. Patient Prefer Adherence 2017;11:1295–1307; S. Kempf L, et al. Am J Med Genet A 2018;176:773–783; 6. Navarini AA, et al. J Eur Acad Dermatol Venereol 2017;31:1792–1799; 7. Mohili SK, et al. Pustular Forms of Psoriasis Related to Autoinflammation. In: Hashkes PJ, Laxer RM, Simon A, eds. Textbook of Autoinflammation. Switzerland; Springer; 2019;471–484; 8. Chung J, et al. J Am Acad Dermatol 2014;71:623–632.

80th American Academy of Dermatology (AAD) Annual Meeting, Boston, MA, USA; March 25–29, 2022.

Disclosures & Acknowledgements

The study was supported and funded by Boehringer Ingelheim. DT has no conflicts of interest to disclose. AP has worked as an investigator and/or speaker and/or advisor for AbbVie, Almirall-Hermal, Amgen, Biogen Idec, Biontec, Boehringer Ingelheim, Celgene, Celltrion, GlaxoSmithKline, Eli Lilly, Galderma, Hexal, Jansen, LEO Pharma, MC2, Medac, Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Rock-Sando Education (J. Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Rock-Sando Education (J. Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Rock-Sando Education (J. Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Rock-Sando Education (J. Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Rock-Sando Education (J. Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Rock-Sando Education (J. Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Rock-Sando Education (J. Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Rock-Sando Education (J. Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Rock-Sando Education (J. Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Rock-Sando Education (J. Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Rock-Sando Education (J. Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Rock-Sando Education (J. Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Rock-Sando Education (J. Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Rock-Sando Education (J. Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Rock-Sando Education (J. Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Rock-Sando Education (J. Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Rock-Sando Education (J. Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Novartis, and Tako Merck Serono, Mitsubishi, MSD, Novartis, Pas International Communications (London, UK) provided writing, editorial, and formatting support, which was contracted and funded by Boekringer Ingelheim.

David Trigos¹, Andreas Pinter², Christian Boisvert-Huneault³, Satomi Kobayashi⁴, Stacie Bell⁵, Kimberley Kallsen⁶, Tristan Gloede⁷, Nobutaka Yagi⁸, Steven Brunette⁷, Yakov Datsenko⁹, Frank Bähner⁶, Emmanuelle Clerisme-Beaty⁶, Peter van de Kerkhof¹⁰





Scan QR code for an interactive, electronic, device-friendly copy of this poster https://bit.ly/3pMvahm

to access an interactive microsite for this Smart poster



33008